On January 9, 2024, Jeffrey Mirviss, EVP & Pres, Periph Intervent of Boston Scientific Corp (NYSE:BSX), sold 15,172 shares of the company. The transaction was filed with the SEC and can be found through this SEC Filing.
Boston Scientific Corporation is a global medical technology leader with a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. The company is known for its innovative devices and therapies that help improve patient outcomes and offer solutions in various medical specialties, including interventional cardiology, cardiac rhythm management, endoscopy, neuromodulation, urology and pelvic health.
Over the past year, the insider has sold a total of 68,082 shares of Boston Scientific Corp and has not made any purchases of the stock. The insider transaction history for the company shows a pattern of 37 insider sells and no insider buys over the same timeframe.
On the day of the insider's recent sale, shares of Boston Scientific Corp were trading at $59.25, resulting in a market cap of $87.327 billion. The price-earnings ratio of the stock stands at 72.70, which is above both the industry median of 29.74 and the company's historical median price-earnings ratio.
The stock's price-to-GF-Value ratio is 1.15, with a GF Value of $51.70, indicating that Boston Scientific Corp is considered Modestly Overvalued according to GuruFocus's valuation.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
